Ignite Creation Date:
2024-05-06 @ 6:42 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05755633
Status:
COMPLETED
Last Update Posted:
2023-03-06
First Post:
2023-02-23
Brief Title:
Role of Day 60 WT1 Assessment on Bone Marrow in Predicting Relapse and Mortality After Allogeneic Stem Cell Transplantation
Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study Overview
Official Title:
Role of Day 60 WT1 Assessment on Bone Marrow in Predicting Relapse and Mortality After Allogeneic Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The rationale of this study is to determine if an association exists between WT1 expression and relapse occurrence in patients with acute myeloid leukemia submitted to allogeneic stem cell transplantation In particular we want to studied WT1 expression level on bone marrow samples of day 60 in terms of predicting power on relapse incidence so as to determine a cut-off value for identify high risk patients
Detailed Description:
This is a retrospective study which will be held on 50 patients with acute myeloid leukemia allografted in the transplant Units of Policlinico Agostino Gemelli in Rome between June 2018 and July 2020 for whom WT1 level was assessed on bone marrow at day 60 after transplant The minimum follow up for surviving patients will be 60 days Patients will be classified according to European Leukemia Net criteria For each patient a total of 24 ml of bone marrow was collected at day 60 post transplant whereas the same quantity of bone marrow was collected from healthy donor during bone marrow harvest procedure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None